RESEARCH ARTICLE

Cyclophilin J Is a Novel Peptidyl-Prolyl Isomerase and Target for Repressing the Growth of Hepatocellular Carcinoma

Jian Chen1,2 *, Shuai Chen1, Jiahui Wang2, Mingjun Zhang1, Zhaohua Gong3, Youheng Wei1, Li Li1, Yuanyuan Zhang1, Xuemei Zhao1, Songmin Jiang1,2 *, Long Yu1

1 State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, P.R. China, 2 Shandong Research Center of Stem Cell Engineering, Yantai Yuhuangding Hospital, Affiliated Hospital of Qingdao University, Yantai, Shandong, P.R. China, 3 Department of Oncology, Yantai Yuhuangding Hospital, Affiliated Hospital of Qingdao University, Yantai, Shandong, P.R. China

* smjiang@fudan.edu.cn (SJ); jianchen2005@gmail.com (JC)

Abstract

Cyclophilin J (CYPJ) is a new member of the peptidyl-prolyl cis/trans-isomerase (PPIase) identified with upregulated expression in human glioma. However, the biological function of CYPJ remained unclear. We aimed to study the role of CYPJ in hepatocellular carcinoma (HCC) carcinogenesis and its therapeutic potential. We determined the expression of CYPJ in HCC/adjacent normal tissues using Western blot, Northern blot and semi-quantitative RT-PCR, analyzed the biochemical characteristics of CYPJ, and resolved the 3D-structure of CYPJ/Cyclosporin A (CsA) complex. We also studied the roles of CYPJ in cell cycle, cyclin D1 regulation, in vitro and in vivo tumor growth. We found that CYPJ expression was upregulated in over 60% HCC tissues. The PPIase activity of CYPJ could be inhibited by the widely used immunosuppressive drug CsA. CYPJ was found expressed in the whole cell of HCC with preferential location at the cell nucleus. CYPJ promoted the transition of cells from G1 phase to S phase in a PPIase-dependent manner by activating cyclin D1 promoter. CYPJ overexpression accelerated liver cell growth in vitro (cell growth assay, colony formation) and in vivo (xenograft tumor formation). Inhibition of CYPJ by its inhibitor CsA or CYPJ-specific RNAi diminished the growth of liver cancer cells in vitro and in vivo. In conclusion, CYPJ could facilitate HCC growth by promoting cell cycle transition from G1 to S phase through the upregulation of cyclin D1. Suppression of CYPJ could repress the growth of HCC, which makes CYPJ a potential target for the development of new strategies to treat this malignancy.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and a leading cause of death in many countries, particularly in East Asia and Africa. The onset and progression
of HCC is related to risk factors such as chronic infection with hepatitis B and C viruses and exposure to hepatocarcinogen aflatoxin B1 [1]. The development of HCC is a multi-step process associated with aberrations in chromosomes and alteration in gene-expression patterns. Many efforts have been made to identify potential tumor suppressor genes in these as well as other regions of the genome, culminating in the discovery of inactivating point mutations in a number of tumor-suppressor genes such as p53, p16, p21, beta-catenin, PTEN, and Rb [2–6]. Despite the completion of the Human Genome Project and the sequencing of increasing number of defined cell lines [7], it remains a challenge to identify novel HCC related genes important for the disease.

Cyclophilins constitute a superfamily of peptide-prolyl isomerases (PPIase), which catalyzes the cis-trans isomerization of peptide bonds on the NH-terminal side of Pro residues [8]. Cyclophilins have been shown to act as chaperons to accelerate protein folding and maturation and play critical roles in signal transduction [9]. The cyclophilin family is comprised of more than fifteen members and was named for their ability to bind the widely used immunosuppressive drug cyclosporine A (CsA) [10]. Cyclophilins have been implicated in many pathological processes, including virus infection [11], rheumatoid arthritis [12], cardiovascular diseases [13] and cancer [14,15]. The precise role of cyclophilins in promoting tumorgenesis, however, has remained largely unknown.

To identify genes involved in the development of HCC, we previously carried out digital differential analyses by comparing the expression of ESTs (expressed sequence tags) in human HCC and normal liver tissues. Among several differentially expressed ESTs, one cDNA upregulated in HCC with a high degree of sequence similarity to human cyclophilin A was chosen for further characterization (unpublished data). The full-length cDNA was cloned and sequenced. It was found to be the new member of the cyclophilin superfamily and was thus named Cyclophilin J (CYPJ, Genbank association number AF146799). Cyclophilin J has also been cloned by another laboratory under the name of PPIL3 (Peptide-Prolyl Isomerase-Like 3) [16], and its upregulation in human glioma was reported [17]. However, the biological function of CYPJ remained unclear. Here, we report a frequent upregulation of CYPJ in HCC which promotes the growth of liver cells. In addition, the inhibition of CYPJ leads to suppression of HCC growth. Our findings are important for a better understanding of the molecular mechanisms underlying the tumorgenesis of HCC, and suggest that CYPJ may serve as a novel therapeutic target for HCC.

Materials and Methods
Cloning of cDNA for CYPJ

The full-length nucleotide sequence of human cyclophilin J was predicted based on its EST sequence and its cDNA was cloned from human multi-tissue cDNA libraries (Clontech, Inc.) by RT-PCR (forward primer: 5'-AAGACTGAGAAATCACGTAGTCC-3'; reverse primer: 5'-CAAGCAGAAGGATGATGCAATC-3').

Samples of primary HCC, adjacent tissues, and cell culture

All samples of primary HCC (T) and adjacent non-tumorous tissues (N) were obtained from Department of Oncology of Yantai Yuhuangding Hospital (Yantai, China). No patient received radiotherapy or chemotherapy before sampling. Most patients with HCC (94.6%) were positive for HBV surface antigen. Fetal liver tissues were obtained from the Gynecology Department of Yantai Yuhuangding Hospital (Yantai, China). All tissues were placed in liquid nitrogen immediately after surgical resection. Hep3B, HepG2, Hela, COS7, and HEK-293T cells were cultured at 37°C with 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM; Gibco-BRL Inc.)
supplemented with 10% fetal calf serum (FCS; Gibco-BRL Inc.), and YY8103, L02, and SK-Hep1 cells were cultured in RPMI-1640 Medium (Gibco-BRL Inc.) supplemented with 10% FCS.

Northern blot
Total RNA was extracted with Trizol reagent (Invitrogen) in accordance with the manufacturer’s protocol. The gene-specific PCR fragments of CYPJ cDNA was labeled with $\alpha^32$P-dATP with random primer kit (Amershan) to hybridize MTN membranes carrying mRNA from 16 human tissues (Clontech) or nylon membranes carrying total RNA from resected liver specimen of 16 cases of HCC and 2 fetal livers. The membranes were prehybridized in Hybridization/Prehybridization solution (50% formamide, 5× SSPE, 10× Denhardt’s solution, 2% SDS, 100 mg/l calf-thymus DNA) at 42°C for 24 h, followed by hybridizing with labeled probe for additional 24 h. The membranes were washed for three times in wash solution (2× SSC/0.1% SDS; 0.5× SSC/0.1% SDS; 0.1× SSC/0.1% SDS) at 65°C before exposure to X-ray film at -80°C for 5 days. As a control, MTN I and MTN II were also hybridized with a 2.0 kb $\beta$-actin (ACTB) cDNA under the same condition, followed by a 4 h exposure to X-film at -80°C. For other membranes, the results of total RNA electrophoresis were used as controls.

Semi-quantitative RT-PCR
cDNA was synthesized using 2 mg of total RNA, SuperscriptII reverse transcriptase (Gibco-BRL Inc.) and Oligo(dT)15 (Promega) according to the manufacturer’s protocols. First-strand cDNA was subjected to RT-PCR amplification on FS-918 DNA Amplifier (Shanghai Fusheng Institute of Biotechnology). To optimize the cycle number, PCR amplifications were performed for 20–37 cycles (94°C 30 s, 60°C 30 s, 72°C 30 s). The products from each cycle were separated and visualized on a 2% agarose gel upon electrophoresis and the growth curve of the PCR products was made according to the amount of PCR products in different cycles to determine the optional cycle number. The semi-quantitative RT-PCR results from 40 HCC samples were scanned with GDS-800 (Bio-Rad) and Annutating Grabber 1T2.51 Scanner software as well as UVP Gelworks ID Advanced Version 2.51 analysis software. The CYPJ mRNA levels in cancer and normal tissues were calculated using a dosage ratio (DR) of the ethidium bromide intensity of CYPJ/ACTB bands in agarose gels [18].

Subcloning
For prokaryotic expression, The ORF of CYPJ was amplified with forward primer 5’-ATAAG AATGCGGCGCTCTGTAAGTTGGTTGGCAT-3’ and reverse primer 5’-ATCGCT CGAGCTG AGCAAATGCGCTCTGTAAGTTGGTTGGCAT-3’ which contained the NotI and Xhol restriction sites respectively, to allow directional subcloning into the pTXB1 vector (New England Biolab). For eukaryotic expression, the coding sequences of CYPJ and CYPA were subcloned in-frame into the pCMV-HA vector (Clontech). The catalytic mutants of CYPJ (R44A, R44A&F49A, and K120A) and CYPA (R55A&F60A) were generated using QuikChange Site-Directed Mutagenesis Kit (STRATAGENE) in both systems. For stable cell line generation, the coding sequence of CYPJ was subcloned in-frame into the pcDNA3.1-myc vector (Clontech).

Expression and purification of recombinant human CYPJ protein
Expression plasmids for CYPJ and the three mutants were transformed into E. coli strain ER2566 (New England Biolab). Recombinant proteins were expressed following a 20 h induction with 0.2 mM IPTG at 22°C, and were subsequently purified by Chintin Beads system...
following the manufacturer’s protocol. Briefly, crude extracts from E. coli containing fusion protein were passed over a 1 ml column at 4°C. The column was washed with >10 column volumes of washing buffer (20 mM HEPES, pH 8.0, 500 mM NaCl, 0.1 mM EDTA, and 0.1% Triton-X100). The column was then quickly flushed with 3 column volumes of fresh cleavage buffer (20 mM HEPES pH 8.0, 50 mM NaCl, 0.1 mM EDTA, and 30 mM DTT). The flow to the column was stopped, and the column was placed at 4°C overnight. CYPJ was eluted using 3 column volumes of cleavage buffer without DTT. Purified protein was analyzed by LC/MS, or kept in PPIase buffer (50 mM HEPES, pH 8.0, and 86 mM NaCl) at 4°C until use.

**PPIase assay**

The assay for PPIase activity of CYPJ and its mutants was modified from the methods of Kofron [19]. The experiment was performed under 8.5°C in a 100 μl system as following: A sample of 2 μl (65.6 μmol/l) of protein was added to 86 μl of PPIase buffer and incubated on ice for 1 h. Reaction was started by the addition of 10 μl chymotrypsin (60 mg/ml solution) and 2 μl peptide substrate N-succinyl-Ala-Ala-Pro-Phe-p-nitroaniline (Sigma) at different concentrations followed by rapid mixing. The absorbance change at 390 nm due to the release of p-nitroaniline was recorded using U-3000 spectrophotometer (Hitachi). CsA inhibition assays were carried out as described above except that the samples were preincubated for 60 min with varying amounts of CsA.

**Crystal structure analysis**

The structure of human CYPJ refined at 2.6 Å resolution [20] was used as a starting model, in which the solvent molecules were omitted, and the structure was further refined using X-ray data collected at 2.0 Å resolution on an R-AXIS IV++ detector [21]. The data were rescaled using HKL2000 software [22], leading to space group P3121 with 11753 unique reflections. Crystallographic refinement was carried out using program CNS [23], and manual refitting of the CYPJ model was performed using program TURBO-FRODO [24]. Solvent molecules were added to the model at late stage of the refinement and only those with B values lower than 50 Å² were included in the final structure.

Single crystals of CYPJ-CsA complex were grown using the hanging drop vapor diffusion method at 293 K under the following conditions: protein solution containing 0.5 mM CYPJ, 1mM CsA, 4% DMSO and 4% isopropanol was mixed at a ratio of 1:1, with the reservoir solution containing 0.1 M Tris-HCl (pH 7.4), 18% PEG 8000 (w/v) and 6% DMSO. Two sets of X-ray data were collected at 293 K with CCD detectors, using a laboratory X-ray source at 2.7 Å resolution for data set 1 and later using Beijing Synchrotron Radiation Facility at 2.4 Å resolution for data set 2, respectively. Both sets of data were processed using software HKL2000. The three-dimensional structure of CYPJ-CsA complex was determined by molecular replacement using program AMoRe [25], and the molecular structure of CYPJ at 2.6 Å resolution was used as the search model [20]. The structure was refined using data sets 1 and 2 successively, in a procedure similar to that used to refine CYPJ. The crystal data and data collection statistics of data collection and crystallographic refinement are shown in S1 Table.

**Eukaryotic expression of CYPJ and selection of stably transfected cells**

The eukaryotic expression plasmids of CYPJ, CYPA and their mutants were transfected into cells using Lipofectamine 2000 reagent (Invitrogen) and the expressed proteins were detected using western blot. For stable cell line generation, HCC cell line SK-Hep1 and liver cell line L02 were transfected with pcDNA3.1-CYPJ or control plasmid pcDNA3.1-myc with Lipofectamine 2000 reagents. Sixty hours after transfection, G418 (Life Technologies Inc.) was added to the
medium at a final concentration of 600 μg/ml. After selection for 3 weeks, clones were selected and expanded. The expression of myc-tagged CYPJ in each individual clone was confirmed by western blot.

**Western blot**

Samples were separated by 10% SDS-polyacrylamide gel electrophoresis, followed by transfer to PVDF membrane. After blocking in phosphate-buffered saline containing 5% bovine serum albumin and 0.1% Tween-20, the membrane was incubated with anti-myc monoclonal antibody (Cell Signaling Technology Inc.), anti-HA monoclonal antibody (Cell Signaling Technology Inc.), anti-Cyclin D1 monoclonal antibody (Santa Cruz Inc.), anti-PPIL3 polyclonal antibody (Abcam) or anti-β-actin monoclonal antibody (Sigma) at room temperature for 2 h, followed by incubation with a peroxidase-linked secondary antibody (CalbioChem) at room temperature for one h. The signals were detected using Western blotting Luminol Reagent (Santa Cruz Inc.).

**Subcellular location, cell cycle, and cell growth analyses**

**Subcellular location analysis.** The coding sequence of CYPJ was inserted in frame into pEGFP-N1 (Clontech). The resultant pEGFP-CYPJ fusion protein-expression plasmid was transfected into Hela cells and visualized using methods described previously [26]. DAPI staining was used to locate the nucleus of Hela cells. In a separate experiment, pCMV-CYPJ plasmid was transfected into Hela cells, and 40 h after transfection, the cells were fixed in 4% paraformaldehyde. The subcellular location of CYPJ was detected by anti-HA mAb and subsequently visualized by Rhodamine-conjugated secondary antibody.

**Cell cycle analysis.** Cells were harvested and fixed in 70% ethanol at -20°C for 24 h before they were resuspended with 10 μl propidium iodide (Life Technologies Inc.) followed by incubation at room temperature for 20 min. Cells were analyzed on a FACS Vantage SE instrument (BD Biosciences Pharmingen, San Diego, CA). The experiments were repeated three times.

**Colony formation assay.** L02 cells (approximately 2×10^5 cells per 60-mm dish) were transfected with 2 μg of pcDNA3.1-CYPJ or empty vector pcDNA3.1-myc with Lipofect2000 reagent. Twenty-four hours after transfection, G418 was added to the medium at a final concentration of 600 μg/ml. Cells were under G418 selection for 3 weeks. Colonies were fixed with methanol and stained with Giemsa to enumerate the transformed foci.

**Cell growth analysis.** Ninety-six-well plates were seeded for triplicate with SK-Hep1-CYPJ cell clones and SK-Hep1-pcDNA control clones at 1×10^3 cells/well. From the first day to the fifth day, cell growth was monitored by absorbance using MTS assay (Promega Inc.). To examine the inhibitory effects of CsA on the growth of several liver cancer cells, 96-well plates were seeded with Hep3B, HepG2, YY8103, QGY, SK-Hep1 and SK-Hep1-CYPJ cells at 1 × 10^3 cells/well. After the treatment with different concentrations of compounds for 72 h, cell viability was monitored by MTS assay compared with control cells treated with PBS.

**Promoter reporter assay for cyclin D1**

The human cyclin D1 promoter-luciferase reporter plasmids -962CD1 and its deletion mutants constructed in pGL3-basic vector were generously provide by Drs. O. Tetsu and F. McCormick (UCSF, San Francisco, CA) [27]. The reporter construct (100 ng/well in 24-well plates) was cotransfected into HEK-293T cells with pCMV-CYPA, pCMV-CYPA(R55A&F60A), pCMV-CYPJ, pCMV-CYPJ(R44A&F49A), or the control pCMV-HA vector alone (200 ng/well for each vector). Thirty hours after transfection, cell lysates were prepared and luciferase activity was determined using Luciferase Assay System. Plasmid pRL-SV40 (Promega; 30 ng/
well) encoding Renilla luciferase was used as an internal control in each transfection. To test the inhibitory effect of CsA on CYPJ-mediated activation of cyclin D1 promoter, CsA was added to the media at different concentrations 12 h after the co-transfection assay described above.

**Quantitative real-time PCR**

Quantification of mRNA was performed by SYBR Green I staining (Takara, Inc.) on an iCycler iQ system (BioRad). To compare the relative levels of gene expression, we used cDNA from a normal adult brain (Clontech, Inc.) to generate standard amplification curve. The primers for amplification are listed in S2 Table. The optimal conditions for PCR were as follows: 40 cycles of three-step PCR (95°C for 50 s, 63°C for 1 min, and 72°C for 30 s) after initial denaturation (95°C for 5 min). The real-time PCR reactions were performed in 25 μl volumes according to the manufacturer’s protocol. The relative mRNA levels of each gene in different cDNA sample were normalized to the internal levels of GAPDH individually. Experiments were carried out twice for each data point, and negative controls were performed to avoid genomic DNA contamination.

**RNAi**

siRNA duplexes (si-CYPJ, 5’-CTGGAAGAGGAGGCAACAG-3’) containing 3’dTdT over-hanging sequences were synthesized at Shanghai GeneChem Co. A control nucleotide (si-control) was also purchased from GeneChem. The sequences of si-CYPJ did not have significant homology to mRNA for other CYPs. The siRNA duplexes were co-transfected with pCMV-CYPJ plasmids and its efficiency to knockdown exogenous CYPJ expression was examined by western blot. Knockdown of endogenous CYPJ mRNA in SK-Hep1 cells was verified by RT-PCR and quantitative real-time RT-PCR. Lentivirus containing sh-RNA for CYPJ knockdown was also generated at Shanghai GeneChem Co., Ltd (sense sequence: gCTGGAAGAGGAGGCAACAG; antisense sequence: CTGTTGCCTCCTCTCTCCAG; loop sequence: TTCAAGAGA).

**Tumor development in athymic nude mice**

Male nude mice (BALB/c-nude, 4–5 week old) were inoculated subcutaneously with CYPJ transfectant and vector control cells (2.5×10⁶ cells suspended in 0.2 ml of PBS) and monitored for tumor development. Mice were sacrificed and tumors were removed 40 days after inoculation.

**In vivo gene transfer in subcutaneous tumor model**

HCC cells SK-Hep1 (6 × 10⁶ cells suspended in 0.2 ml of PBS) were implanted into the left flanks of BALB/c-nude mice, and 7 days later, when tumors reached 3–4 mm in diameters, an intra-tumor injection of LV-CYPJ-RNAi and LV-non-silencing control at a titer of 3 × 10⁷ TU in 20 μl PBS was administrated, and the same treatment was repeated two days later. Mice were monitored daily and tumor sizes were measured every 3 days. Mice were sacrificed 23 days after the final injection and the tumors were removed for analyses [28].

**Immunohistochemical staining**

The harvested tissue was sliced into 4 micrometers sections. The sections were deparaffined in xylene and rehydrated in alcohol. Endogenous peroxidase was perished by 3% H₂O₂ for 10 min. Antigen retrieval was achieved by treatment of microwave in citrate acid buffer (pH 6.0) twice, and then blocked in 3% goat serum (Boster China) for 15 min in 37°C for any none specific reaction, incubated in primary antibody in 4°C overnight, and washed in PBS for three
times. The slides were further incubated with biotin labeled secondary antibody for 30 min, washed three times in PBS, incubated in SABC complex for 25 min, washed again in PBS for three times, and visualized using 3,3′-diaminobenzidine tetra hydrochloride (DAB/H2O2) and counterstained with hemotoxylin. In lentivirus-mediated gene knockdown experiments, a DAPI staining was used to detect the nucleus of tumor cells, and the green fluorescence (GFP carried by lentivirus) was used to indicate transfection efficiency.

Statistics
Statistical difference was analyzed using student’s T-test where $P<0.05$ suggested statistically significant difference.

Ethics Statement
This study involved using of human tissues, in which written informed consents from the donors or their next of kin were obtained for the use of these samples in research. All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. The use of human tissues and animal experiments were approved by the Ethics Committee of Yantai Yuhuangding Hospital, China. Mice were sacrificed by cervical dislocation performed by an individual with a demonstrated high degree of technical proficiency.

Results
Elevated CYPJ expression in hepatocellular carcinoma
The tissue distribution of human CYPJ was determined by Northern hybridization with a $\alpha$-32P dATP-labeled gene-specific fragments as a probe (Fig 1A). A 1.3 kb transcript was detected in human adult tissues (MTN I and II, Clontech), with high levels of expression in the heart, liver, and testis, moderate levels of expression in skeletal muscle, kidney, pancreas, and spleen. CYPJ mRNA was barely detectable in the brain, placenta, lung, thymus, prostate, small intestine and colon, and no signal was detected in peripheral blood leukocyte. In addition to the 1.3 kb transcript, a 2.5 kb transcript could also be detected in the testis, which suggested the existence of another variant of human CYPJ specifically expressed in the testis.

The high level of human CYPJ in the liver and the possible link between cyclophilins and cancer cells prompted us to check its expression in HCCs, a malignancy with high incidence in China. The expression of human CYPJ mRNA was upregulated in the majority of (15 out of 16) tumorous specimens compared with adjacent normal tissues (Fig 1B; $P<0.001$). We also examined the expression of human CYPJ in fetal livers and found that CYPJ had higher expression in fetal livers than in normal adult livers (Fig 1B). Independently, we examined the expression of CYPJ in 40 pairs of HCC/adjacent non-cancerous tissues by semi-quantitative RT-PCR, and the results were in agreement with that from the Northern blot analyses, in which human CYPJ was found to be elevated in 26/40 (65%) tumor specimens (Fig 1C). The relationship of elevated CYPJ expression with clinical grades of HCC was also examined (Fig 1D). CYPJ was found to be upregulated in 12/22 (54.5%) HCC patients with Grade II disease and in 28/34 (82.5%) HCC patients with Grade III disease ($P<0.01$). In addition, the level of CYPJ in another 15 pairs of HCC/adjacent non-cancerous tissues samples was investigated by Western blot. Result showed that in 9/15 (60%) HCC samples an elevated CYPJ expression was observed (Fig 1E), which was consistent with the Northern result. In 3/15 (20%) samples the expression level of CYPJ remained unchanged while in 3/15 (20%) samples decreased. These data suggested that CYPJ was upregulated in HCC tissues which might play a role in the progression of the malignancy.
CYPJ is a novel PPIase which binds to and is inhibited by CsA. The deduced amino acid sequence of CYPJ showed 50% similarity with human CYPA and 72% similarity with CYP-10 of *C. elegans*. CYPJ also contained the PPIase consensus sequence 

```
[F/Y]–X(2)–[S/T/C/N/L/V]–X–[F/H]–[L/I/V/M/N]–[L/I/V/M]–X(2)–[F/H]–[L/I/V/M]–X–Q–[A/G]–G
```

These characteristics indicated that CYPJ may be a novel peptidyl-prolyl *cis*-trans-isomerase. To characterize CYPJ biochemically, we expressed and purified recombinant CYPJ in *E. coli* (Fig 2A). The relative molecular weight of the purified protein was 19379.34 Da as determined by LC/MS.

The enzymatic activity of human CYPJ was determined. In the chymotrypsin-coupled assay with different concentration of the peptide substrate, the recombinant human CYPJ appeared to follow Michaelis-Menten kinetics (Fig 2B). The value of kcat and K_M were estimated to be 34.2±8.3 s⁻¹ and 814±152 μM by a double reciprocal Lineweaver-Burke plot of 1/v against 1/[S], yielding a kcat/K_M value of (4.20±1.29)×10⁴ M⁻¹S⁻¹. Several key amino acids (R44, F49, K120) have been previously reported to be important for the catalytic activity of CYPA protein [30]. The corresponding mutants were generated in CYPJ (R44A, R44A&F49A, and K120A) and their residual PPIase activities were detected and compared with that of the wild-type CYPJ protein. The R44A, R44A&F49A, and K120A CYPJ mutants displayed 57%, 32% and 87% of the wild type enzyme activity respectively, consistent with the roles of these residues in catalysis (Fig 2C). In addition, the inhibitory effect of CsA on PPIase activity of CYPJ was also
Fig 2. Biochemical characteristics of CYPJ protein and the 3D-structure of CYPJ/CsA complex. (A) Expression and purification of CYPJ. Line 1: uninduced E. coli lysate; lines 2–5: transformed E. coli was induced by 0.2 mM IPTG for 2, 3, 4 and 5 h, respectively; line 6: purified tagged CYPJ; line 7: the chitin tag was removed by DTT treatment. (B) Michaelis-Menten kinetics of CYPJ. (C) Effects of several site mutations (R44A, R44A&F49A, and K120A) to the peptidyl-prolyl cis/trans-isomerase activity of CYPJ. ** P<0.01. (D) Catalytic curves of inhibition. a, PPIase assay with 13.1 μM recombinant CYPJ protein; b-e, PPIase assays with 13.1 μM CYPJ and 1, 4, 8 or 16μM CsA, respectively; f, reference assay with no CYPJ or CsA. (D) and (E), 3D-structure of CYPJ-CsA complex. (D) CYPJ-CsA complex structure. CYPJ is shown as ribbon, and CsA is shown in green. The structure of CYPJ-CsA complex refined at 2.4 Å resolution contains two molecules of the complex in an asymmetric unit. In the final structure model the two CYPJ chains consist of 159 and 160 amino acid residues, respectively (the last two C-terminal residues in molecule A and the last one in molecule B could not be located). (E) A part of hydrogen bonding interactions between CYPJ and CsA. The side chains of Arg44, Gln52, Asn92, His110 and Tyr115 are shown in red and CsA in green. Hydrogen bonds are shown as dotted lines.
examined. CsA inhibited CYPJ in a dose-dependent manner (Fig 2D) with an IC$_{50}$ of 12 μM in the current assay.

The 3D-structures of CYPJ and the CYPJ/CsA complexes were determined to explore the catalytic mechanism and key residues involved in CsA binding. The structure of CYPJ refined at 2.0 Å resolution showed similarity to that of CYPA (S1A Fig) as previously described [20]. His43, Arg44 and Gln52 were conserved active-site residues located in the shallow pocket, and Arg44 displayed flexible conformation as shown by comparison with CYPA and its various complexes (S1A and S1B Fig), suggesting that Arg44 is an important residue and its flexible conformation is essential for binding different substrates. This was consistent with the experimental data that mutation of Arg44 could significantly weaken its activity (Fig 2C). The structure of CsA in the CYPJ-CsA complex was similar to that in the CYPA-CsA complex structure (Fig 2E and 2F) [31]. However, the side chains of MeLeu4 and MeLeu6 displayed different conformations in the two structures, which belong to the effector domain (residues 4–8) of CsA and were involved in the interactions of CsA with calcineurin (Cn) [32]. On the other side of the cyclic undecapeptide, the cyclophilin-binding domain of CsA (residues 1–3, 9–11) interacted with CYPJ (Fig 2E). The hydrogen-bonding interactions between CYPJ and CsA were listed in S3 Table, including several C-H…O hydrogen bonds. Most of these interactions were conserved in CYPA-CsA complex structure (Fig 2F). Arg44 was involved in the hydrogen-bonding interactions with CsA, which well accounted for the experimentally observed inhibition of CsA on PPIase activity of CYPJ.

Subcellular localization of CYPJ

Three methods were used to determine the subcellular localization of CYPJ: immunofluorescence microscopy for direct visualization of EGFP-fused CYPJ, indirect visualization for HA-tagged CYPJ in Hela cells, and immunohistochemical staining of HCC tissue sections. EGFP-fused CYPJ expression plasmid pEGFP-N1-CYPJ was transfected into Hela cells, and EGFP--CYPJ fusion protein was directly visualized by fluorescence microscope (Fig 3A). HA-tagged CYPJ-expressing plasmid pCMV-CYPJ was transfected into Hela cells, and the tagged CYPJ was detected by immunofluorescence (Fig 3B). CYPJ was found in both cytoplasm and the nucleus, with more distribution in the nucleus, which was also confirmed in HCC tissue by immunohistochemical analysis (Fig 3C and 3D). The preferential localization of CYPJ in the nucleus suggested that it might have a nuclear function.

Involvement of CYPJ in the regulation of cell cycle

To assess the potential role of CYPJ in the regulation of cell cycle, we examined and compared cell distribution of human hepatic cancer cell line SK-Hep1 cells transfected with empty vector pCMV-HA, cells overexpressing either CYPJ or PPIase-impaired CYPJ mutant from pCMV-CYPJ or pCMV-CYPJ(R44A&F49A) respectively, cells with CYPJ knockdown by CYPJ-siRNAs and inhibition of CYPJ PPIase activity by CsA. Compared with empty vector-transfected control cells, overexpression of CYPJ induced an increase in cell population in the S phase (from 35.46% to 58.09%, $P<0.01$, N = 3) and a corresponding decrease in population in G0-G1 phase (from 61.76% to 39.36%, $P<0.01$, N = 3), with the percentage of G2-M phase cells remained unchanged (Fig 4A). In contrast, when the PPIase activity was impaired, the CYPJ(R44A&F49A) mutant could no longer induce this shift in cell cycle ($P>0.05$, N = 3) (Fig 4A).

In RNAi experiments, we synthesized 3 small interference RNAs (siRNAs) specific to the coding sequence of CYPJ, and found that one of the siRNAs complex (si-J-1, 352 nt-370 nt of CYPJ mRNA) could decrease the expression of co-transfected exogenous CYPJ protein...
efficiently (Fig 4B). We further examined its effect on the expression of endogenous CYPJ gene in HCC cell line SK-Hep1 (Fig 4C). The siRNAs was specific for CYPJ, for it did not affect the expression of CYPA mRNA (Fig 4C). CYPJ knockdown resulted in a decreased population of S-phase SK-Hep1 cells (from 36.9% to 24.2%, $P<0.01$, $N = 3$) and increased G0-G1 phase cells (from 52.0% to 66.9%, $P<0.01$, $N = 3$) (Fig 4D). In addition, this result was further supported by the inhibition of CYPJ PPiase activity via CsA. After a 48 h treatment of SK-Hep1 cells with 4 $\mu$M CsA, a significant increase in the percentage of G0-G1 phase cells (from 51.7% to 60.4%, $P<0.01$, $N = 3$) was observed accompanied by a significant decrease in S phase cells (from 36.7% to 25.2%, $P<0.01$, $N = 3$) with G2-M phase unchanged (Fig 4F).

Together, these results indicated that CYPJ could promote the transition of cell cycle from G1 phase to S phase, and this function was dependent on the PPiase activity of CYPJ. This might contribute to the enhanced growth of HCC.

CYPJ modulates cyclin D1 expression

Given the function of CYPJ in the G1-S transition, we next examined gene expression related to G1-S phase entry in CYPJ transfected cells by quantitative real-time RT-PCR. As shown in Fig 5A, the expression of RB1, cyclin D1 (CCND1), CDK2, CDK4, and p27 was examined. Compared with control cells, CYPJ overexpression upregulated the expression of cyclin D1 and repressed the expression of p27. In a complementary experiment, knockdown of CYPJ led to a decrease in the expression of cyclin D1 (Fig 5B and 5C).

To further evaluate the mechanism by which cyclophilins regulate the transcription of cyclin D1, we examined the effects of overexpressing CYPJ and CYPA on cyclin D1 promoter using cyclin D1-luciferase reporter constructs (-962CD1), as described previously [33]. Compared with control cells transfected with empty vector, CYPJ and CYPA overexpression stimulated the transcription of cyclin D1 promoter for about 3 folds and 7 folds, respectively (Fig 5D). Interestingly, the stimulation of the cyclin D promoter by CYPJ and CYPA is dependent...
Fig 4. Effects of CYPJ on cell cycle distribution. (A) Effects of CYPJ and CYPJ(R44A&F49A) overexpression on cell cycle distribution of SK-Hep1 cells. ** P<0.01, N = 3. (B) Knockdown of exogenously enforced CYPJ expression by three different short interference RNAs. The most effective siRNA complex si-J-1 was selected for further analyses. (C) Knockdown of endogenous CYPJ expression by short interference RNA. The expression of CYPA was not affected by the si-J-1 transfection. β-actin was used as internal control. (D) Effects of CYPJ knockdown on cell cycle distribution of SK-Hep1 cells. ** P<0.01, N = 3. (E) Effects of CsA inhibition on cell cycle distribution of SK-Hep1 cells. Cells were treated with 4 μM CsA for 48 h before the experiment. ** P<0.01, N = 3.

doi:10.1371/journal.pone.0127668.g004
on their PPlase activity, as the PPlase-deficient mutants CYPJ(R44A&F49A) and CYP A (R55A&F60A) failed to activate cyclin D1 promoter (Fig 5D). The CYPJ-mediated activation
of cyclin D1 promoter was also inhibited by CsA treatment in a dosage-dependent manner (Data not shown). It is thus likely that the effect of CYPJ on cell cycle progression can be attributed at least in part to its activation of the transcription of cyclin D1.

The cyclin D1 promoter contains binding sites for several transcription factors, including AP1, EtsA, EtsB, EtsC, TCF1 and CREB (Fig 5E). To determine sites required for cyclophilin mediated cyclin D1 activation, we examined the effects of CYPJ and CYP A on a series of cyclin D1 promoter mutants with each site deleted (Fig 5F). The results indicated that, deletion of any transcription factor binding site significantly diminished the activation of cyclin D1 promoter by CYPJ \( (P<0.01) \), and the deletion of AP1, EtsA, EtsC or TCF1 affected the activation of cyclin D1 promoter by CYP A \( (P<0.01) \). These results suggested that cyclophilin signals might regulate cyclin D1 transcription through multiple ways, which differs from other proteins such as FAK [34] or SNIP1 [35] that activate cyclin D1 promoter through a unique transcription factor binding site.

**Elevated expression of CYPJ promotes HCC**

To investigate the role of CYPJ in HCC tumorigenesis, normal hepatocytes L02 cells and HCC cell line SK-Hep1 were used to generate stable cell lines expressing CYPJ, and cell growth was monitored. After transfection and selection for 3 weeks, we obtained a series of clones that stably expressed CYPJ (Fig 6A; L1, 2, 5, and 6 in L02 cell line, and S2, 3, 4, and 5 in SK-Hep1 cell line). L3, L4 and S1 clones are control cells stably transfected with empty vector. SK-Hep1 clones S2, S3, S5 and empty vector clone S1 were seeded in 96 well plates (1000 cells per well), and cell growth was examined in a 5-day MTS assay. As shown in Fig 6B, all three selected SK-Hep1 clones grew faster than control cells.

In colony formation assay, pcDNA-CYPJ plasmid and control plasmid pcDNA3.1-myc were transfected into L02 cells under selection with G418 for 3 weeks, and colony numbers were calculated. L02 cells transfected with CYPJ showed a significant increase in the number of colonies (about 2 folds, Fig 6C and 6D). These effects were reproducible and was observed in 3 independent experiments \( (P<0.01) \). Colonies were selected, and exogenously expressed CYPJ was validated by western blot (data not shown). These results suggested that elevated expression of CYPJ might contribute to the transformation of liver cells.

To further determine the role of CYPJ in tumorigenesis, we selected three stable clones (L02 clones L1, L2 and SK-Hep1 clone S2) with higher exogenous expression and inoculated them to nude mice (control clones L3, L4 and S1 were also used). We inoculated control cells and stable cell clones to the same nude mice: one on left shoulder and one on right shoulder. As shown in Fig 6E, the stable cell clones gave rise to much larger tumors than the vector controls. In 10–14 days, tumors emerged. Tumors were later removed at day 40 from the mice and were individually weighed. Tumors originated from the L02-CYPJ cells weighed 392% and 472% respectively, of those of the vector controls, and tumors originated from the SK-Hep1-CYPJ cells weighed 346% of the vector controls (Fig 6F). The exogenous expression of CYPJ was also detected in L02-CYPJ-originated tumors by immunohistochemistry (Fig 6G). These results indicated that CYPJ could promote liver tumor formation not only in vitro but also in vivo.

**Targeting CYPJ diminishes the growth of liver cancer cells**

As exogenous expression of CYPJ can promote the growth of liver cells, we examined the effects of inhibition of CYPJ on liver cancer cell growth. The CYPJ inhibitor CsA was used to inhibit the activity of CYPJ, and lentivirus mediated RNAi was used to knockdown CYPJ expression. CsA inhibited the growth of several liver cancer cells, such as Hep3B, HepG2, YY8103 and SK-Hep1 (Fig 7A and 7B). As CsA can block the activities of most cyclophilin
family members including CYPJ, the extent to which the growth inhibition by CsA can be attributed to CYPJ remained to be further established.

Using the optimal siRNA CYPJ knockdown sequence previously described, we made lentivirus carrying the corresponding shRNA of CYPJ. By quantitative real-time RT-PCR, we validated the efficiency of CYPJ shRNA lentivirus to knock down the expression of CYPJ in the transduced SK-Hep1 cells (data not shown). We then inoculated SK-Hep1 cells to nude mice. After 5–7 days, 10 mice were selected containing tumors of nearly the same volume (about 10–30 mm³). We then carried out CYPJ knockdown by injecting five mice with control viruses and other five with CYPJ shRNA viruses. The injection was repeated once in two days. The size of each tumor was determined every three days thereafter (Fig 7C). The volume of CYPJ knockdown tumors was significantly smaller than the control tumors (\(P < 0.05\) at day 26, and \(P < 0.01\) at day 29 and 32). At day 32, CYPJ knockdown tumors were 40% smaller than the controls (Fig 7C and 7D). Cell nuclei were stained by DAPI, and infected cells were detected by fluorescence microscope using the GFP marker in transduced cells (Fig 7E). These results demonstrated that knockdown of CYPJ could significantly diminish the growth of liver cancer cells in vivo, and CYPJ may serve as a new target for liver cancer therapy.

Discussion

In this study, we characterized CYPJ both in vitro and in vivo. We demonstrated that CYPJ was a bona fide PPIase that was sensitive to inhibition by CsA, albeit with low potency. We found that upregulation of CYPJ was related to the clinical grades of HCC. We further demonstrated that overexpression of CYPJ caused an increase in cell proliferation and knockdown of CYPJ inhibited HCC cell growth both in vitro and in vivo, thus establishing CYPJ as a potential target for developing novel anti-cancer agents.

The dominant nuclear accumulation of CYPJ is similar to some other prolyl isomerases, such as Pin1, CYP4A, and FKBP25. Previous studies have shown that CYP4A could bind to YY1 and alter its transcriptional activity [36]. Pin1, a PPIase specific for phosphotyrosyl-prolyl residues, can interact with phosphorylated c-Jun, and dramatically increases its ability to activate the cyclin D1 promoter [37]. In addition, Pin1 has also been shown to interact with and activate p53 upon DNA damage [38, 39]. FKBP25 was suggested to be recruited to preribosomes to chaperone one of the protein components of the ribosome large subunit [40]. It is a regulator of the p53 pathway, which induces the degradation of MDM2 and activation of p53 pathway [41].

In this study, we found that CYPJ promoted cell cycle transition from G1 to S phase in a PPIase-dependent manner through the upregulation of cyclin D1. This was in accordance with the report that CsA, the CYPJ inhibitor, inhibits colon carcinoma cell growth by delaying cell cycle progression and induction of necroptosis [42]. Interestingly, both CYP4A and CYPJ were capable of upregulating the expression of cyclin D1 in a PPIase-dependent manner, suggesting that these two members of cyclophilin family are functionally redundant for the positive regulation of Cyclin D1 expression. That CYPJ-induced transcription of cyclin D1 was dependent...
on multiple transcription factors suggested that it is likely to activate an early step of a physiological signaling pathway that is integrated in the CCND1 promoter.

Using the stable SK-Hep1 and L02 cell lines, we found that increased CYPJ expression accelerated tumor cell growth in vitro and in vivo. And knockdown of CYPJ expression by lentivirus-mediated siRNA in SK-Hep1 cells significantly diminished tumor growth in vivo. In
addition, it was reported that the CYPJ inhibitor CsA could inhibit the growth of human transi-
tional cell carcinoma of bladder cell lines EJ cells in vivo [43]. Another study also found that
tumor size was significantly reduced in a mouse B-lymphoid tumor model following CsA treat-
ments [44]. These results suggested that expression of CYPJ is necessary and sufficient to sup-
port tumor growth. It has been previously reported that CYPA is upregulated in several tumor
types including non-small cell lung cancer, pancreatic cancer, breast cancer, colorectal cancer,
quamous cell carcinoma and melanoma [45]. CYPA promotes the growth of non-small cell lung cancer in vivo [46] while downregulation of cyclophilin A by siRNA diminishes non-
small cell lung cancer cell growth and metastasis [47]. PPIL1 has also been reported to be upre-
gulated in colon cancer tissues, and capable of promoting the growth of colon cancer cells
through SNW1/SKIP and/or stathmin [29]. Cyclophilin D is a component of permeability
transition-pore, which was found to be overexpressed in breast cancer tissues, acting as a sup-
pressor of apoptosis [48]. These findings suggested that promotion of tumor growth may be a
shared property of members of the cyclophilin family.

Our results clearly demonstrated that inhibitors of CYPJ are of benefit in HCC therapy.
CsA, an immunosuppressive drug, is a potent inhibitor of CYPA. CsA has been used in liver
cancer cells in combination with taxol to overcome drug resistance [49]. However, CsA has
drawbacks as cancer therapeutic agent, due to its immunosuppressive activity [50]. Non-im-
munosuppressive CsA derivatives and novel inhibitors designed based on the structure of
CYPJ and CYPJ/CsA complex may lead to improvement to clinical outcome for patients with
HCC.

Conclusions
Our study demonstrated that expression of the PPIase CYPJ is likely to facilitate tumor growth
by promoting cell cycle transition from G1 to S phase in a PPIase-dependent manner through
the upregulation of cyclin D1. This enables CYPJ to be a promising therapeutic target for hepa-
tocellular carcinoma and for developing novel anti-cancer agents.

Supporting Information
S1 Fig. 3D-Structures of human CYPJ. (A) Ribbon diagram of CYPJ showing the active site
pocket. Helices and β-strands were shown in green and blue, respectively. Disulfide bridges
were shown in pink. The N and C termini were labeled. Side chains of His43, Arg44 and Gln52
were shown in red. (B) Side chains of His43, Arg44 and Gln52 of CYPJ in structures refined at
2.0 Å resolution and at 2.1 Å resolution (using two different X-ray data sets) were shown in red
and green, respectively. Those in the reported structures of the unligated CYPA, the CYPJ-CsA
complex, as well as CYPA in complexes with dipeptide AP and tetrapeptide AAPF were also
superimposed with those in CYPJ, which were shown in light blue, yellow, dark blue and
pink, respectively.

S1 Table. Crystal and statistical data and crystallographic refinement.

S2 Table. Primer sequences for quantitative real-time RT-PCR.

S3 Table. Hydrogen bonding interactions between CYPJ and CsA

(TIF)

(DOCX)

(DOCX)

(DOCX)
Acknowledgments
We thank numerous individuals participated in this study.

Author Contributions
Conceived and designed the experiments: JC SJ. Performed the experiments: JC SC MZ YW LL YZ XZ JW. Analyzed the data: ZG JW. Contributed reagents/materials/analysis tools: LY. Wrote the paper: JC JW SJ.

References
1. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999; 353: 1253–1257. PMID: 10217098
2. Azechi H, Nishida N, Fukuda Y, Nishimura T, Minata M, Katsuma H, et al. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology. 2001; 60: 346–354. PMID: 11408803
3. Elmileik H, Paterson AC, Kew MC. Beta-catenin mutations and expression, 249serine p53 tumor suppressor gene mutation, and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma. J Surg Oncol. 2005; 91: 218–283. PMID: 16121349
4. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006; 25: 3778–3786. PMID: 16799619
5. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, et al. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 1997; 57: 3471–3477. PMID: 9270015
6. Yeh KT, Chang JG, Chen YJ, Chen ST, Yu SY, Shih MC, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma. J Invest Surg. 2006; 18: 123–129. PMID: 10705874
7. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268–274. PMID: 16959974
8. Galat A, Metcalfe SM. Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol. 1995; 63: 67–118. PMID: 7538221
9. Bukrinsky MI. Cyclophilins: unexpected messengers in intercellular communications. Trends Immunol. 2002; 23: 323–325. PMID: 12103338
10. Metcalfe SM. Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol. 1995; 63: 67–118. PMID: 7538221
11. towers GJ, Hatzioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med. 2003; 9: 1138–1143. PMID: 12897779
12. Kim H, Kim WJ, Jeon ST, Koh EM, Cha HS, Ahn KS, et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol. 2005; 116: 217–224. PMID: 15993649
13. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: promising new target in cardiovascular therapy. Circ J. 2010; 74: 2249–2526. PMID: 20962430
14. Lee J, Kim SS. An overview of cyclophilins in human cancers. J Int Med Res. 2010; 38: 1561–1574. PMID: 21309470
15. Yao Q, Li M, Yang H, Chai H, Fisher W, Chen C. Roles of cyclophilins in cancers and other organ systems. World J Surg. 2005; 29: 276–280. PMID: 15706440
16. Zhou Z, Ying K, Dai J, Tang R, Wang W, Huang Y, et al. Molecular cloning and characterization of a novel peptidylprolyl isomerase (cyclophilin)-like gene (PPIL3) from human fetal brain. Cytogenet Cell Genet. 2001; 92: 231–236. PMID: 11435694
17. Qi ZY, Hui GZ, Li Y, Zhou ZX, Gu SH, Ying K, et al. cDNA microarray in isolation of novel differentially expressed genes related to human glioma and clone of a novel full-length gene. Chin Med J (Engl). 2001; 118: 799–805. PMID: 15989758
18. Jiang J, Yu L, Huang X, Chen X, Li D, Zhang Y, et al. Identification of two novel human dynein light chain genes, DNL2A and DNL2B, and their expression changes in hepatocellular carcinoma tissues from 68 Chinese patients. Gene. 2001; 281: 103–113. PMID: 11750132
19. Kofron JL, Kuzmic P, Kishore V, Colon-Bonilla E, Rich DH. Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry. 1991; 30: 6127–6134. PMID: 2096221
20. Huang LL, Zhao XM, Huang CQ, Yu L, Xia ZX. Structure of recombinant human cyclophilin J, a novel member of the cyclophilin family. Acta Crystallogr D Biol Crystallogr. 2005; 61: 316–321. PMID: 15735342

21. Hu H, Huang CQ, Liu HL, Han Y, Yu L, Bi RC. Crystalization and preliminary X-ray crystallographic studies of human cyclophilin J. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005; 61: 216–218. PMID: 16510998

22. Minor W, Tomchick D, Otwinowski Z. Strategies for macromolecular synchrotron crystallography. Structure. 2000; 8: R105–110. PMID: 10801499

23. Brunger AT, Adams PD, Clore GM, DeLano WL, Gross P, Grosse-Kunstleve RW, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998; 54: 905–921. PMID: 9757107

24. Roussel A, Cambillau C. TURBO-FRODO, Silicon Graphics Partner Geometry Dictionary. Mountain View, CA: Silicon Graphics; 1991.

25. Minor W, Tomchick D, Otwinowski Z. Strategies for macromolecular synchrotron crystallography. Structure. 2000; 8: R105–110. PMID: 10801499

26. Chen S, Saijin H, Zeng X, Xi J, Liu X, Li X, et al. Isolation and functional analysis of human HMBOX1, a homeobox containing protein with transcriptional repressor activity. Cytogenet Genome Res. 2006; 114: 131–136. PMID: 16825764

27. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398: 422–426. PMID: 10201372

28. Mikol V, Kallen J, Pfugl G, Walkinshaw MD. X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J Mol Biol. 1993; 234: 1119–1130. PMID: 8263916

29. Jin L, Harrison SC. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A. 2002; 99: 13522–13526. PMID: 12357034

30. Zydowsky LD, Etzkorn FA, Chang HY, Ferguson SB, Stolz LA, Ho SI, et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1992; 1: 1092–1099. PMID: 13389797

31. Roche KC, Wiechens N, Stolz LA, Ho SI, et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1992; 1: 1092–1099. PMID: 13389797

32. Yang WM, Inouye CJ, Seto E. Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity. J Biol Chem. 1995; 270: 15183–15189. PMID: 7541038

33. Zydowsky LD, Etzkorn FA, Chang HY, Ferguson SB, Stolz LA, Ho SI, et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1992; 1: 1092–1099. PMID: 13389797

34. Roche KC, Wiechens N, Stolz LA, Ho SI, et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1992; 1: 1092–1099. PMID: 13389797

35. Roche KC, Wiechens N, Stolz LA, Ho SI, et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1992; 1: 1092–1099. PMID: 13389797

36. Yang WM, Inouye CJ, Seto E. Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity. J Biol Chem. 1995; 270: 15183–15189. PMID: 7541038

37. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001; 20: 3459–3472. PMID: 11432833

38. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 2002; 419: 853–857. PMID: 12397362

39. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature. 2002; 419: 849–853. PMID: 12397361

40. Gudavicius G, Dilworth D, Serpa JJ, Sessler N, Petrotchenko EV, Borchers CH, et al. The prolyl isomerase, FKBP25, interacts with RNA-engaged nucleolin and the pre-60S ribosomal subunit. RNA. 2014; 20: 1014–1022. doi: 10.1261/rna.042648.113 PMID: 24840943

41. Ohcocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, et al. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett. 2009; 583: 621–626. doi: 10.1016/j.febslet.2009.01.009 PMID: 19166840

42. Werneck MB, Hottz E, Bozza PT, Viola JP. Cyclophilin A inhibits colon cancer cell growth independently of the calcineurin pathway. Cell cycle. 2012; 11: 3997–4008. doi: 10.4161/cc.22222 PMID: 22992618
43. Lin J, Wang YH, Zhang YH, Tian Y. Proliferation effects of sirolimus, cyclosporine A and mycophenolate mofetil on human transitional cell carcinoma cells. Zhonghua Yi Xue Za Zhi. 2012; 92: 388–391. PMID: 22490898

44. D’Costa S, Slobod KS, Hurwitz JL. Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth? Leuk Lymphoma. 2003; 44: 139–142. PMID: 12691154

45. Lee J. Role of cyclophilin A during oncogenesis. Arch Pharm Res. 2010; 33: 181–187. doi:10.1007/s12272-010-0200-y PMID: 20195816

46. Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 2005; 65: 8853–8860. PMID: 16204056

47. Qian Z, Zhao X, Jiang M, Jia W, Zhang C, Wang Y, et al. Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metalloproteinase 9. BMC Cancer. 2012; 12: 442. doi:10.1186/1471-2407-12-442 PMID: 23031673

48. Schubert A, Grimm S. Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor. Cancer Res. 2004; 64: 85–93. PMID: 14729611

49. Lin HL, Lui WY, Liu TY, Chi CW. Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer. 2003; 88: 973–980. PMID: 12644839

50. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66: 807–815. PMID: 1715244